Brought to you by 
Advanced Accelerator Applications completes €23mm late round
25 Jun 2015
Executive Summary
Advanced Accelerator Applications (molecular nuclear medicine, diagnostics, and therapeutics) raised €23mm ($25.7mm) in what the company calls a crossover financing, led by Adage Capital Management. New investors included Rock Springs Capital Management and funds and accounts managed by Rock Springs Capital. Some of the proceeds will help the company continue Phase III work on its lead radiopharmaceutical Lutathera (Lu-177-labeled somatostatin analog) for neuroendocrine cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advanced Accelerator Applications completes €23mm late round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice